STOCK TITAN

Vivani Medical Announces Private Placement Equity Financing

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
private placement

Vivani Medical (VANI) announced a private placement expected to raise approximately $5.1 million from two members of its board of directors. Chairman Gregg Williams and director Aaron Mendelsohn are purchasing 5,049,506 common shares at $1.01 each under a November 15, 2026 agreement. Gross proceeds exclude estimated offering expenses. Closing is expected on or about November 23, 2026, subject to customary conditions.

Vivani intends to fund research and clinical development of NPM-139, its semaglutide implant, and other candidates, alongside general corporate needs. It expects the proceeds and existing cash resources to fund operations into the third quarter of 2027. The financing follows SLIM-1 Phase 1 results: no NPM-139 participants experienced treatment-related adverse events, and no serious adverse events occurred in the study. Vivani anticipates a Phase 2 dose-ranging weight maintenance trial beginning in 2027.

Loading...
Loading translation...
6 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Private placement is expected to provide approximately $5.1 million in gross proceeds from two directors. 5.6% of market cap
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Offering proceeds and existing cash resources are expected to fund operations into the third quarter of 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Proceeds are intended to support NPM-139 and other product candidates’ research and clinical development.
  • Minor pointNPM-139 had no treatment-related adverse events; five of 10 Wegovy controls had treatment-related gastrointestinal events.
  • Minor pointSLIM-1 reported no serious adverse events; implant insertions and removals were completed without complications.
  • Minor point. Forward-looking: it has not happened yet and may not happen.NPM-139’s Phase 2 dose-ranging weight maintenance trial is anticipated to begin in 2027.

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Issuance of 5,049,506 common shares at $1.01 each dilutes existing shareholders.

News Explained

The expected gross proceeds equal 73.4 days of third-quarter 2026 operating cash use, before offering expenses.

Vivani agreed to issue 5,049,506 new common shares to two directors in a private placement expected to close on or about November 23, 2026, subject to customary conditions; if completed, the added shares increase the share count and reduce existing holders’ percentage ownership.

Sources and calculations
  • Offering gross against the last reported quarterly operating outflow, in days at that rate $5,100,000 / ($6,390,000 / 92) = 73.4 days

Key Figures

Shares offered: 5,049,506 shares Offering price: $1.01 per share Gross proceeds: Approximately $5.1 million +2 more
Shares offered
5,049,506 shares
Private placement
Offering price
$1.01 per share
Private placement
Gross proceeds
Approximately $5.1 million
Before estimated offering expenses
Expected closing
On or about November 23, 2026
Subject to customary closing conditions
Expected operating runway
Into the third quarter of 2027
Offering net proceeds together with existing cash, cash equivalents and restricted cash

Previous Private placement Reports

1 past event · Latest: Mar 27
Same Type 1 event
  1. Mar 27

    private placement

    24h Move
    +2.7%

    Prior placement funded development and extended stated cash runway into Q2 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement, share purchase agreement, at-the-market, open-label, +1 more
5 terms
private placement financial
"announced a private placement of its common stock"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
share purchase agreement financial
"pursuant to a Share Purchase Agreement"
A share purchase agreement is a written contract that outlines the terms and conditions for buying and selling shares of a company. It specifies details like the price, number of shares, and any special conditions, ensuring both buyer and seller agree on the transaction. For investors, it provides clarity and legal protection, making sure the purchase is clear and enforceable.
at-the-market financial
"priced “at-the-market” under the rules and regulations"
"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.
open-label medical
"a four-week, open-label, active-controlled trial"
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
active-controlled medical
"a four-week, open-label, active-controlled trial"
An active-controlled study is a trial in which the new treatment is compared against an existing, approved treatment instead of a placebo. For investors, this matters because results show how the new product stacks up against the current standard—like testing a new phone by comparing it to a popular model rather than to no phone—so positive results can indicate real competitive advantage and clearer market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

ALAMEDA, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced a private placement of 5,049,506 shares of its common stock at an offering price of $1.01 per share purchased by Gregg Williams, the Chairman of the Company’s board of directors, and Aaron Mendelsohn, another member of the Company’s board of directors, pursuant to a Share Purchase Agreement dated November 15, 2026. The gross proceeds to the Company from the private placement are expected to be approximately $5.1 million, before estimated offering expenses. The financing follows the Company’s November 12, 2026 announcement of positive top-line results from SLIM-1, its first-in-human Phase 1 clinical trial of NPM-139, which support advancing NPM-139 toward a Phase 2 dose-ranging weight maintenance trial anticipated to begin in 2027.

SLIM-1 was a four-week, open-label, active-controlled trial in 20 otherwise healthy overweight or obese participants, with 10 receiving low-dose NPM-139 and 10 receiving the starting dose of Wegovy (0.25 mg/week semaglutide injection). No NPM-139 participants experienced adverse events reported as treatment related. Five of 10 Wegovy control group participants experienced adverse events reported as treatment related, all of which were gastrointestinal. No serious adverse events were reported in the study, and implant insertions and removals were brief and successfully completed without complications.

The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC. The private placement is expected to close on or about November 23, 2026, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the private placement to fund ongoing research and clinical development of its semaglutide implant, NPM-139, and the Company’s other product candidates, as well as for working capital and general corporate purposes. The Company anticipates that the net proceeds from the offering, together with its existing cash, cash equivalents and restricted cash, will fund the Company’s operations into the third quarter of 2027.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Vivani Medical, Inc.

Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. 

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential or the planned development thereof, and its technology, strategy, cash position and financial runway, and the closing of the private placement. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays, and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Vivani’s expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (the “SEC”) including the factors described in Vivani’s most recent Quarterly Report on Form 10-Q filed with the SEC on November 12, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.

Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462

Investor and Media Relations Contact:
Jami Taylor
Investor and Media Relations Advisor
investors@vivani.com
(415) 506-8462


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is Vivani Medical raising in its private placement, and at what price?

Vivani expects approximately $5.1 million in gross proceeds from 5,049,506 common shares priced at $1.01 each, before estimated offering expenses. The buyers are board chairman Gregg Williams and director Aaron Mendelsohn. Closing is expected on or about November 23, 2026, subject to customary closing conditions.

How long does Vivani Medical expect its cash to last after the financing?

Vivani anticipates funding operations into the third quarter of 2027 using the offering’s net proceeds together with existing cash, cash equivalents and restricted cash.

How was Vivani Medical’s SLIM-1 trial designed?

SLIM-1 was a four-week, open-label, active-controlled Phase 1 trial in 20 otherwise healthy overweight or obese participants. Ten received low-dose NPM-139, and 10 received the starting dose of Wegovy, a 0.25 mg/week semaglutide injection. Open-label means treatment assignments were known.

Keep reading